SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 30, 2020
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction
2390 East Orangewood Avenue, Suite 500
Anaheim, California 92806
(Address of Principal Executive Office) (Zip Code)
(Registrant’s telephone number, including area code)
(Former Name or Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On January 30, 2020, BioCorRx Inc. (the “Company”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has confirmed the Company has been awarded a second year of funding to support the development of a 3-month implantable depot pellet of naltrexone for the treatment of Opioid Use Disorder. The Company refers to this treatment as BICX102. The amount awarded, $2,831,838, remains unchanged from the previously announced Notice of Award issued to the Company in January 2019.
On January 30, 2020, the Company issued a press release announcing the events described in this Item 8.01. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Date: January 30, 2020
/s/ Lourdes Felix
Chief Financial Officer